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Thanks to Singh and co-authors[1] for their meta-analysis addressing a 5 
controversial topic. Post-operative pain control protocols following total knee 6 
arthroplasty (TKA) are essential to successful outcomes, with peri-articular 7 
injections (PAIs) being an important component.  Liposomal bupivacaine (Exparel) 8 
is claimed to provide a slow release of local anesthetic, for approximately 72 hours, 9 
and has been promoted as a superior component of PAI. Since its introduction, 10 
numerous studies show contradicting efficacy. A meta-analysis could provide a 11 
substantial amount of clarity.  Unfortunately, your study methodology has 12 
numerous flaws, which render the conclusions invalid. 13 
Literature on liposomal bupivacaine compares different analgesic 14 
techniques. In your paper, you grouped these into 1) infiltration, 2) femoral nerve 15 
block, 3) multimodal pain-management.  In your analysis, you examined them both 16 
separately and together, however the study’s conclusions were derived from the 17 
sum of all three, thereby introducing confounding variable bias. When examining 18 
liposomal bupivacaine’s efficacy, it is scientifically appropriate to analyze studies 19 
involving other PAI cocktails. For example, femoral nerve blocks introduce 20 
confounders by acting over a different sensory distribution, as well as delay 21 
discharge due to quadriceps weakness.  If you analyze the PAI group alone, there is 22 
no improvement (0.07 +/- 0.09 days, p = 0.48) in length of stay.  We believe this 23 
finding would reach even greater significance if it included the data presented in our 24 
paper (2.32 +/- 0.53 liposomal bupivacaine versus 2.31 +/- 0.93 control, p = 0.93), 25 
which was included in your study (article #2) but left out of the analysis for unclear 26 
reasons.[2]  27 
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The meta-analysis claims improved pain scores on post-operative day (POD) 28 
0 and 2, but day 1 scores were not different, which is illogical.  This may be in part 29 
due to including pain scores from our paper in the POD 2 analysis; however, our 30 
pain scores were averaged from 24 hours after surgery to the time of discharge, as 31 
detailed in our methods, with some patients discharged on POD 3 [2]. Additionally, if 32 
you only compare treatment with other PAI studies, there is no difference on POD 1 33 
(0.23 +/- 0.17, p = 0.20) or 2 (0.07 +/- 0.18, p = 0.69) in your analysis. Further, while 34 
your meta-analysis demonstrated a difference in PAI on POD zero (1.21 +/- 0.31, p = 35 
0.00), the majority of data (74.5%) is from a single paper [3], which obviates the 36 
scientific credibility and proposed benefits of a meta-analysis.  Additionally, authors 37 
of this particular study[3] have financial conflicts of interest, imparting bias.  We 38 
appreciate Sing and co-authors[1] have no conflicts; however, author conflicts in the 39 
studies comprising the meta-analysis should have been considered and discussed.  40 
We respectfully appreciate your effort on the important and controversial 41 
topic of liposomal bupivacaine’s efficacy as a component of PAI; however, the study 42 
methodology has numerous critical flaws, which affect the results and render the 43 
conclusions invalid.  Based on substantial increase in the cost and lack of 44 
scientifically proven efficacy, we do not advocate the use of liposomal bupivacaine 45 
in routine practice. 46 
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